Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.68 |
| ▸ | CNR1 | P21554 | 13/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TOP2A | P11388 | 1/20 | 0.52 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6167019 | 1.00 | CNR2 (0.68) | CNR2CNR1KDM4EKMT2ATOP2A | |
| SCHEMBL11852714 | 0.81 | TOP2A (0.55) | CNR2CNR1KDM4EKMT2ATOP2A | |
| SCHEMBL4717954 | 0.81 | KDM4E (0.63) | CNR2CNR1KDM4EKMT2ATOP2A | |
| SCHEMBL29433778 | 0.81 | KDM4E (0.63) | CNR2CNR1KDM4EKMT2ATOP2A | |
| SCHEMBL4717957 | 0.81 | KDM4E (0.63) | CNR2CNR1KDM4EKMT2ATOP2A | |
| SCHEMBL11858118 | 0.81 | TOP2A (0.55) | CNR2CNR1KDM4EKMT2ATOP2A | |
| SCHEMBL10330772 | 0.79 | TOP2A (0.59) | CNR2CNR1KDM4EKMT2ATOP2A | |
| SCHEMBL11858912 | 0.79 | TOP2A (0.59) | CNR2CNR1KDM4EKMT2ATOP2A | |
| SCHEMBL9144791 | 0.78 | TOP2A (0.58) | CNR2CNR1KDM4EKMT2ATOP2A | |
| SCHEMBL2080555 | 0.78 | TOP2A (0.66) | CNR2CNR1KDM4EKMT2ATOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882689-B1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8476429-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-8211910-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| EP-2463274-A1 | Tri-or tetra-substituted-3-aminopyrrolidine deritatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-13 | — | — | EP | disclosed |
| EP-2130827-B1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-7875722-B2 | having high antibacterial activity and high safety, at high yield and in a simple manner; one-pot process | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20100063279-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2130827-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7563805-B2 | 7-[3-Amino-3,4-dimethylpyrrolidine-1-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid: quinoline bactericide; broad spectrum, strong antibacterial activity for Grampositive/-negative including multiple resistant cocci; side effect reductcion; drug design | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| EP-1882689-A1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2008-01-30 | — | — | EP | disclosed |
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-23 | — | — | US | disclosed |
| EP-1134219-B1 | CYCLOALKYL-SUBSTITUTED AMINOMETHYLPYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6573260-B1 | Antibiotics | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1134219-A1 | CYCLOALKYL-SUBSTITUTED AMINOMETHYLPYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
| US-3984548-A | Substituted pyrido[1,2,3,-de]-1,4-benzoxazines as bactericides | RIKER LABORATORIES, INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | QTRT1, RRS1, LAS1L | CNR2 2423/4885CNR1 956/4885KDM4E 2926/4885 |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | AAAS, NPEPPS, TEAD4 | CNR2 4292/4885CNR1 3891/4885KDM4E 3137/4885 |
| US-20100063279-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | NQO2, QPCT, QARS1 | CNR2 2273/4885CNR1 1819/4885KDM4E 2852/4885 |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | TLR5, TEAD4, NAALAD2 | CNR2 4436/4885CNR1 4267/4885KDM4E 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.